Puig Brands, S.A.

Spain · ES0105777017 · reports in EUR · Europe

Four figures

From the annual report for the year to Dec 31, 2025. Each line says what it is based on.

Revenue growth
Revenue +5.3% in the year to Dec 31, 2025, on the year before.
Return on equity
It earned 15% on its shareholders' equity in the year to Dec 31, 2025.
Equity and assets
Equity is 46% of its assets, and operations brought in cash in the year.
Price and earnings
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2025, consolidated, in EUR.

€5.0B

revenue

16%

operating margin

€594M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2023Dec 2024Dec 2025
Revenue€4.3B€4.8B€5.0B
Operating profit€693M€759M€812M
Net profit to shareholders€465M€531M€594M
Earnings per share€0.86€0.94€1.05
Cash from operations€556M€740M€859M
Cash€853M€883M€1.0B
Total assets€7.7B€8.6B€8.5B
Equity€959M€3.5B€3.9B

What they do

In the company's own words, from the annual report.

Puig opera en tres segmentos: Fragancias y Moda, Maquillaje y Cuidado de la Piel, a través de marcas propias y licencias. Puig se basa en un sistema único de marcas, lideradas por personalidades únicas, con las que establece relaciones duraderas y productivas, a través de valores compartidos y la misma visión de construcción de marca. La mayor parte del negocio generado por Puig se basa en sus marcas propias, destacando Carolina Herrera, Jean Paul Gaultier, Rabanne, Charlotte Tilbury, Nina Ricci, Dries Van Noten, Penhaligon’s, L’Artisan Parfumeur, Kama Ayurveda, Loto del Sur, Byredo, Dr.Barbara Sturm, Apivita y Uriage. Además, Puig comercializa marcas licenciadas, destacando Christian Louboutin, Adolfo Domínguez y Antonio Banderas.

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.